DexCom, Inc. (NASDAQ:DXCM) Receives $89.33 Average Price Target from Analysts

Shares of DexCom, Inc. (NASDAQ:DXCM) have received a consensus rating of “Moderate Buy” from the twenty-six ratings firms that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold recommendation, seventeen have given a buy recommendation and three have given a strong buy recommendation to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $88.8571.

A number of equities research analysts have recently commented on DXCM shares. JPMorgan Chase & Co. dropped their target price on DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a research report on Friday, October 31st. Wells Fargo & Company set a $93.00 price target on DexCom and gave the stock an “overweight” rating in a research report on Friday, October 31st. William Blair raised DexCom to a “strong-buy” rating in a report on Thursday, July 31st. The Goldman Sachs Group cut their price objective on DexCom from $104.00 to $89.00 and set a “buy” rating for the company in a research report on Wednesday, October 1st. Finally, Weiss Ratings reaffirmed a “hold (c-)” rating on shares of DexCom in a research note on Wednesday, October 8th.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 1,466 shares of the firm’s stock in a transaction dated Thursday, September 4th. The shares were sold at an average price of $80.00, for a total value of $117,280.00. Following the transaction, the executive vice president directly owned 105,223 shares of the company’s stock, valued at approximately $8,417,840. This trade represents a 1.37% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Michael Jon Brown sold 500 shares of DexCom stock in a transaction dated Friday, August 15th. The stock was sold at an average price of $80.29, for a total value of $40,145.00. Following the completion of the sale, the executive vice president owned 94,102 shares in the company, valued at approximately $7,555,449.58. The trade was a 0.53% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last ninety days, insiders have sold 5,383 shares of company stock valued at $434,274. Insiders own 0.32% of the company’s stock.

Institutional Trading of DexCom

A number of institutional investors have recently made changes to their positions in the company. Andra AP fonden purchased a new position in DexCom in the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC acquired a new stake in shares of DexCom in the second quarter valued at about $26,000. SJS Investment Consulting Inc. lifted its stake in shares of DexCom by 4,800.0% in the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock worth $26,000 after buying an additional 384 shares in the last quarter. Zions Bancorporation National Association UT acquired a new position in DexCom during the first quarter worth about $27,000. Finally, Financial Consulate Inc. acquired a new position in DexCom during the third quarter worth about $29,000. 97.75% of the stock is owned by institutional investors and hedge funds.

DexCom Price Performance

NASDAQ:DXCM opened at $55.00 on Tuesday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The company has a 50 day moving average price of $69.24 and a 200-day moving average price of $77.65. DexCom has a 1-year low of $54.11 and a 1-year high of $93.25. The firm has a market cap of $21.45 billion, a price-to-earnings ratio of 38.19, a price-to-earnings-growth ratio of 1.43 and a beta of 1.40.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, October 30th. The medical device company reported $0.61 EPS for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a net margin of 13.29% and a return on equity of 30.41%. The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter last year, the business earned $0.45 earnings per share. The firm’s revenue was up 21.6% on a year-over-year basis. DexCom has set its FY 2025 guidance at EPS. Equities research analysts forecast that DexCom will post 2.03 EPS for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.